Moderate-term, low-dose corticosteroids for rheumatoid arthritis

Criswell, Lindsey A.; Sems, Kelly M.; Welch, Vivian; Shea, Beverley; Wells, George A.; Suarez‐Almazor, María E.

doi:10.1002/14651858.cd001158

Cited by 53 publications

(37 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, all patients with VL described to date received concomitant oral steroids at a low dose, leading to steroids being partially blamed for lower cellular host defense and increased risk of infection (5). The risk of infection in patients with RA is complicated to evaluate as multiple factors such as age, presence of comorbidities, use of biological therapies, and the persistent activity of the disease itself contribute to the risk (5).…”

Section: Visceral Leishmaniasis In the Mediterranean Areamentioning

confidence: 99%

Visceral Leishmaniasis in the Mediterranean area

Reina

Corominas

2018

Eur J Rheumatol

View full text Add to dashboard Cite

Section: Visceral Leishmaniasis In the Mediterranean Areamentioning

confidence: 99%

Visceral Leishmaniasis in the Mediterranean area

Reina

Corominas

2018

Eur J Rheumatol

View full text Add to dashboard Cite

“…It analysed 10 studies with 320 patients and the overall results showed an improvement in all parameters with GC therapy. These included pain scales, joint scores, morning stiffness, fatigue and improvement in acute phase reactant levels (Criswell et al, 2000;Gotzsche & Johansen, 2004). The therapeutic benefit is much greater than that of other anti-inflammatory treatments, with an effect size of about 1.25.…”

Section: Anti-inflammatory Effects Of Low Dose Therapymentioning

confidence: 99%

The Clinical Role of Glucocorticoids in the Management of Rheumatoid Arthritis

Al-Mossawi¹,

Kirwan²

2012

Rheumatoid Arthritis - Treatment

View full text Add to dashboard Cite

“…104,105 Although glucocorticoids inhibit inflammation, they also induce the expression of macrophage migration inhibitory factor (MIF), which in turn, possesses the unique ability to override the inhibitory effect of glucocorticoids on immune and inflammatory responses. 106 The MIF (-173GC) variant has recently been linked to clinical response in numerous inflammatory conditions.…”

Section: Glucocorticoidsmentioning

confidence: 99%

Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies

O’Rielly

Rahman

2010

PGPM

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic heterogeneous autoimmune disorder of unknown etiology resulting in inflammation in the synovium, cartilage, and bone. Genetic factors play an important role in susceptibility to RA as the heritability of RA is between 50% and 60%, with the human leukocyte antigen (HLA) locus accounting for at least 30% of overall genetic risk. Outside the major histocompatibility complex (MHC) region, six additional risk loci have been identified and validated including PTPN22, STAT4, PADI4, CTLA4, TNFAIP3-OLIG3, and TRAF1/C5. Genetic factors are also important in RA pharmacotherapy due to the gene-dependent activity of enzymes involved in the pharmacokinetics and/or pharmacodynamics of RA medications. Indeed, there is great variability in drug efficacy as well as adverse events associated with any anti-rheumatic therapy and genetics is thought to contribute significantly to this inter-individual variability in response. This review will summarize the genetic factors that have been implicated in the pathogenesis of RA, and how these determinants may factor into the potential pharmacogenetics of this disease. We will also review the therapeutic agents that are currently being utilized or presently being evaluated in the treatment of RA, along with potential pharmacogenetic markers that have been proposed for such medications.

show abstract

Moderate-term, low-dose corticosteroids for rheumatoid arthritis

Cited by 53 publications

References 43 publications

Visceral Leishmaniasis in the Mediterranean area

Visceral Leishmaniasis in the Mediterranean area

The Clinical Role of Glucocorticoids in the Management of Rheumatoid Arthritis

Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies

Contact Info

Product

Resources

About